Key result
Thrombolysis for acute PE requires clinical, biomarker, and imaging stratification to optimize patient benefit.
Why the study?
Identifying patients at highest risk of death from acute pulmonary embolism is critical to select those who would benefit most from thrombolytic therapy.
This review discusses the evolving role of thrombolytic therapy and risk stratification in the management of acute pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Supports risk stratification before thrombolysis in acute PE; leaves open optimal tool validation in prospective studies.
Acute pulmonary embolism (PE) is a common clinical condition with presentations that may vary from asymptomatic subsegmental emboli to massive vascular obstruction and shock with high risk of death. Identifying patients at highest risk for death is critical to select those who would benefit most from thrombolytic therapy. New and evolving clinical prediction models, serum tests, and imaging modalities are being used to improve our ability to identify potential thrombolytic candidates. We review the evolution of the present guidelines on the management of PE, specifically regarding the evolving role of thrombolytics; outcomes following thrombolytic therapy, including mortality, hemorrhage, hemodynamic improvement, and prevention of chronic thromboembolic pulmonary hypertension; and our strategy for risk stratification of pulmonary embolism.
No takes yet. Share an insight, caveat, or question.
Vyas et al. (2012) conducted a review in Acute pulmonary embolism. Thrombolytic therapy was evaluated. Thrombolytic therapy for acute pulmonary embolism requires careful risk stratification using clinical prediction models, serum tests, and imaging to identify patients who would benefit most.
Synapse has enriched 10 related papers. Consider them for comparative context: